What’s Happening in the RRP Community
What’s Happening in the RRP Community
Stay informed on the latest developments in RRP research, treatment advances, clinical trial opportunities, and advocacy efforts. This is your source for news that matters to patients, caregivers, and clinicians navigating the evolving landscape of recurrent respiratory papillomatosis care.
Younger Adults with RRP Face More Recurrences, Large Chinese Study Finds
A major multicenter study from China examined more than a decade of data on adult-onset recurrent respiratory papillomatosis (AoRRP). Researchers found that patients diagnosed at younger ages experienced more frequent recurrences, higher disease burden, and more aggressive disease patterns than those diagnosed later in adulthood.
FDA Approves New Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
In a landmark moment for the recurrent respiratory papillomatosis (RRP) community, the FDA has granted accelerated approval to Voceryq®, a first-in-class plasmid DNA-based immunotherapy for adults with RRP. The approval represents the second FDA-approved treatment for RRP and introduces a novel approach that targets the HPV infection underlying the disease.
When RRP Spreads to the Lungs: Understanding a Rare and Severe Adult-Onset Case
Pulmonary involvement in recurrent respiratory papillomatosis (RRP) is exceptionally rare but can be one of the most serious complications of the disease. A 2025 case report describes an adult patient whose RRP spread into the lung tissue despite treatment with systemic bevacizumab, ultimately requiring surgical removal of part of the lung.
Gender-Neutral HPV Vaccination Could Prevent Thousands of RRP Cases, Study Finds
A large modeling study from Taiwan found that gender-neutral HPV vaccination programs could significantly reduce HPV-related diseases, including recurrent respiratory papillomatosis (RRP). Researchers projected that vaccinating both boys and girls with the 9-valent HPV vaccine would prevent thousands of RRP cases, reduce deaths, and generate substantial healthcare cost savings over the long term.
HPV-11 and Severe Pediatric Recurrent Respiratory Papillomatosis: Understanding the Link Between Viral Genotype and Disease Severity
A recently published study examined whether HPV genotype influences the severity of recurrent respiratory papillomatosis (RRP) in children. Researchers found that children with HPV-11 experienced significantly more aggressive disease, requiring more surgeries and demonstrating higher disease severity scores than those with HPV-6.
Gardasil as Adjunctive Therapy for Juvenile Recurrent Respiratory Papillomatosis: Evidence from South Africa
A groundbreaking study from South Africa explored the use of Gardasil® as an adjunctive therapy for juvenile-onset recurrent respiratory papillomatosis (JoRRP). Researchers observed substantial reductions in disease severity, longer intervals between surgeries, and lower tracheostomy rates, offering new evidence supporting the potential role of HPV vaccination in established RRP cases.
Statement Opposing Adoption of Single-Dose “One Is Enough” HPV Vaccination Policy in the United States and Other High-Resource Settings
RRPF strongly opposes the adoption of single-dose HPV vaccination as a replacement for the multi-dose regimen in the United States. The evidence supporting "One Is Enough" applies to cervical cancer prevention and cannot be extended to HPV 6/11-driven diseases like RRP.
RRPF Nominated for Inaugural Prix Galien Patient First Award in Honor of Michael J. Fox
RRPF has been nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J. Fox, recognizing our work to bring patient voices into the regulatory record. The winner will be announced October 29 in New York City.
New Study Confirms What Patients Have Been Saying: Bevacizumab Offers a Better Quality of Life
A new study comparing patient experiences with surgery and systemic bevacizumab found that 83% of patients preferred bevacizumab and reported better voice, breathing, less pain, and improved mental health. Here's what the research found.
Clinical Trial: Pembrolizumab and Lenvatinib for RRP With Pulmonary Involvement
A new clinical trial led by Dr. Sarah Pai is investigating combination immunotherapy for adults with RRP that has spread to the lungs. Learn about the study and how to participate.
BackTable ENT Podcast Discusses Immunotherapy for Adults with RRP
Dr. Aaron Friedman joins the BackTable ENT podcast to discuss immune-directed therapy for RRP, including the FDA-approved PAPZIMEOS vaccine and what clinical trial data reveal about durable treatment responses in adults.
New Study Examines the Patient Perspective of Living with Recurrent Respiratory Papillomatosis
A newly published study in The Laryngoscope draws on data from the RRPF/CoRDS Patient Registry to quantify what our community has long known: RRP impacts far more than the airway. Here's what the research found.
First Patients Dosed With Papzimeos: A Historic Milestone for the RRP Community
After years of advocacy and research, the first patients have now received doses of Papzimeos. RRPF President Kim McClellan reflects on what this historic moment means for our community.
Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP
RRPF has published a new position statement outlining an evidence-based management algorithm for adults with RRP, developed by key opinion leaders with direct patient input.
Update on INO-3017 FDA Review and RRPF Advocacy
INOVIO's Biologics License Application for INO-3017 has been accepted by the FDA. RRPF shares an update on the review process and our advocacy for the accelerated approval pathway.
FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
INOVIO announced that the FDA has accepted its Biologics License Application for INO-3107 for review as a potential treatment for adults with RRP. Here's what this milestone means for our community.
RRPF Hosts Webinar Following the FDA Approval of Papzimeos
The RRPF invited Dr. Clint Allen, Dr. Simon Best, Dr. Geoffrey Young, and Precigen to our webinar series to chat about Papzimeos and answer a few of the questions from our RRP community.
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO announced it has completed the rolling submission of its Biologics License Application for INO-3107. RRPF President Kim McClellan shares what this milestone means for our community.
RRPF President, Kim McClellan, interviewed for 2026 International Drug Repurposing Conference
RRPF President, Kim McClellan, was recently interviewed for the 2026 International Drug Repurposing Conference. Kim's understanding of the RRP patient journey is valuable beyond measure as she tirelessly advocates for you and your loved ones every day.
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis
The FDA has approved Papzimeos, the first and only treatment for adults with RRP. RRPF celebrates this historic milestone and reflects on what it means for our community.